Company: CYTK
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001193125-25-039426
Chunk: 56

Company: CYTOKINETICS INC
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 56
---
), 14 or 15(d) of the Exchange Act until we file a post-effective amendment that indicates the termination of the offering of the shares of our common stock made by this prospectus and will become a part of this prospectus supplement and the accompanying prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: Cytokinetics, Incorporated 350 Oyster Point Boulevard South San Francisco, California 94080 United States of America Attn: Investor Relations (650) 624-3000 S-15

Up to $500,000,000

Common Stock

PROSPECTUS SUPPLEMENT

Jefferies

February 27, 2025

PART II INFORMATION NOT REQUIRED IN THE PROSPECTUS Item 14. Other Expenses of Issuance and Distribution. The following table sets forth an estimate of the fees and expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the issuance and distribution of the securities being registered. All amounts shown are estimates.

| SEC Registration Fee                     
 Legal Fees and Expenses                  |     | $ |     | -1) 
  (2 |
| Nasdaq Global Select Market Listing Fees |     |   |     |  -2 |
| Accounting Fees                          |     |   |     |  -2 |
| Printing and Miscellaneous Fees          |     |   |     |  -2 |
| Total                                    |     | $ |     |  -2 |

| (1) | In accordance with Rules 456(b) and 457(r), the registrant is deferring payment of all applicable registration                                                                                                    
 fees for the securities offered by this prospectus, other than with respect to the registration fees applicable to the offering of up to $500,000,000 of common stock pursuant to the sales agreement prospectus. |

| (2) | The amount of securities and number of offerings are indeterminable and the expenses cannot be estimated at                                                                         
 this time. An estimate of the aggregate expenses in connection with the sale and distribution